Bridgeway Capital Management, LLC Galecto, Inc. Transaction History

Bridgeway Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.6 - $0.89 $30,000 - $44,500	-50,000 Reduced 40.62%	73,100 $57,000
Q4 2023 Feb 14, 2024	SELL	$0.52 - $0.78 $26,000 - $39,000	-50,000 Reduced 28.89%	123,100 $88,000
Q2 2022 Aug 15, 2022	SELL	$1.22 - $2.74 $12,200 - $27,400	-10,000 Reduced 5.46%	173,100 $299,000
Q4 2021 Feb 14, 2022	SELL	$2.3 - $3.58 $229,999 - $358,000	-100,000 Reduced 35.32%	183,100 $555,000
Q3 2021 Nov 15, 2021	BUY	$3.59 - $5.0 $269,250 - $375,000	75,000 Added 36.04%	283,100 $1.02 Million
Q2 2021 Aug 16, 2021	BUY	$4.63 - $8.0 $963,503 - $1.66 Million	208,100 New	208,100 $1.05 Million

21.2K

Ticker GLTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,395,700
Market Cap $119M
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.